Related Experiment Videos
Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells
Abstract:
Matrix metalloproteinase-1 (MMP-1), also called interstitial collagenase, may play an important role in the pathogenesis of atherosclerosis and atherosclerotic plaque rupture. We investigated the effects of fluvastatin on MMP-1 expression in human vascular endothelial cells (ECs). The addition of fluvastatin decreased the basal MMP-1 levels in the culture media of ECs in a time-dependent (0 to 48 hours) and dose-dependent (10(-)(8) to 10(-)(5) mol/L) manner. On the other hand, fluvastatin did not affect tissue inhibitor of metalloproteinase-1 levels. Collagenolytic activity in conditioned media of ECs was also dose-dependently reduced by fluvastatin. The effect of fluvastatin on MMP-1 expression was completely reversed in the presence of mevalonate or geranylgeranyl-pyrophosphate, but not in the presence of squalene. Inhibition of Rho by C3 exoenzyme also significantly decreased MMP-1 expression in ECs. Our findings revealed that fluvastatin decreases MMP-1 expression in human vascular ECs through inhibition of Rho.
Insights
Fluvastatin reduces matrix metalloproteinase-1 (MMP-1) in human vascular endothelial cells. This cholesterol-lowering drug inhibits MMP-1 via the Rho pathway, potentially impacting atherosclerosis.
Area of Science:
- Cardiovascular Biology
- Molecular Pharmacology
Background:
- Matrix metalloproteinase-1 (MMP-1), or interstitial collagenase, is implicated in atherosclerosis and plaque rupture.
- Understanding factors influencing MMP-1 expression is crucial for cardiovascular disease research.
Purpose of the Study:
- To investigate the impact of fluvastatin on MMP-1 expression in human vascular endothelial cells (ECs).
Main Methods:
- ECs were treated with varying concentrations and durations of fluvastatin.
- MMP-1 levels, tissue inhibitor of metalloproteinase-1 (TIMP-1), and collagenolytic activity were measured.
- The role of Rho signaling was assessed using C3 exoenzyme and specific pathway intermediates.
Main Results:
- Fluvastatin significantly decreased basal MMP-1 levels in ECs in a time- and dose-dependent manner.
- Collagenolytic activity was reduced by fluvastatin, while TIMP-1 levels remained unaffected.
- The inhibitory effect of fluvastatin on MMP-1 was reversed by mevalonate or geranylgeranyl-pyrophosphate, and Rho inhibition also decreased MMP-1.
Conclusions:
- Fluvastatin effectively reduces MMP-1 expression in human vascular ECs.
- The mechanism involves the inhibition of Rho signaling pathway.
- These findings suggest a potential role for statins in modulating atherosclerotic processes via MMP-1 regulation.